Willett, C., Caverly Rae, J., Goyak, K.O., et al. “Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology.” ALTEX (Online First), doi: http://dx.doi.org/10.14573/altex.1401281

Bishop P. and Willett C. (2013). “The Use and Acceptance of Other Scientifically Relevant Information (OSRI) in the US EPA Endocrine Disruptor Screening Program.” Birth Defects Research, Part B: Developmental and Reproductive Toxicology. Published online: 22 OCT 2013, DOI: 10.1002/bdrb.21077 (Summary here.)

Jacobs M.N., Laws S.C., Willett K., Schmieder P., Odum J., Bovee T.F. (2013). “In vitro metabolism and bioavailability tests for endocrine active substances: What is needed next for regulatory purposes?” ALTEX 30(3):331-51.

Vinken M., Landesmann B., Goumenou M., Vinken S., Shah I., Jaeschke H., Willett C., Whelan M., Rogiers V. (2013). “Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury.” Toxicological Sciences: published online August 14, 2013 doi:10.1093/toxsci/kft177

Willett, C. (2012). Tox21C: The AOP Approach Applied to REACH axlr8-progress-report-2012, in Alternative Testing Strategies: Progress Report 2012 & AXLR8-3 Workshop Report on a ‘Roadmap to Next Generation Safety Testing Under Horizon 2020,’ eds. Troy Seidle and Horst Spielmann, AXLR8 Consortium.  (Also presented at the AXLR8 Workshop, 10 June 2012, Berlin Germany.)

Stephens, M.L., et al. (2012). Accelerating the Development of 21st-Century Toxicology: Outcome of a Human Toxicology Project Consortium Workshop. Toxicological Sciences 125(2): 327-334.